Pharmaceutical Technology

DECEMBER 16, 2022

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. of 7MM sales.

Marketing 59

Marketing Side effects Sales Safety 59

Medico Reach

FEBRUARY 8, 2023

from 2022 to 2030, the pharma industry will reach USD 9,241.34 million by 2030. AI can lead to faster research, combining and extracting data into usable formats, making clinical trials more efficient and saving time. from 2023 to 2030. Poised to grow at a CAGR of 29.4% billion in 2022 and will expand at a CAGR of 10.3%

Pharma 52

Pharma Medicine Marketing Prospecting 52

European Pharmaceutical Review

MARCH 24, 2023

In NASH, excess fat in the liver can lead to progressive disease, including inflammation, liver cell injury and fibrosis, which are associated with increased risk for cardiovascular disease and liver morbidity and mortality. Pegozafermin also has a favourable safety and tolerability profile, with few gastrointestinal (GI) side effects.

Medical 82

Medical Side effects Safety Pharmaceutical 82